Cassava Sciences Inc

SAVA11 Dec 2024
Healthcare
$2.89
-0.02 (-2.42%)
Lowest Today
$2.76
Highest Today
$2.89
Today’s Open
$2.89
Prev. Close
$2.89
52 Week High
$42.2
52 Week Low
$2.78
BUY
SELL
To Invest in Cassava Sciences Inc

Cassava Sciences Inc

Healthcare
SAVA11 Dec 2024
₹
-0.02 (-2.42%)
1M
3M
6M
1Y
5Y
Low
$2.76
Day’s Range
High
$2.89
2.76
52 Week Low
$2.78
52-Week Range
52 Week High
$42.2
2.78
1 Day
-
1 Week
-1.19%
1 month return
-89.26%
3 month return
-89.4%
6 month return
-84.56%
1 Year return
-89.51%
3 Years return
-93.54%
5 Years return
+71.59%
10 Years return
-
Institutional Holdings
BlackRock Inc
6.69
Vanguard Group Inc
5.24
Vanguard Total Stock Mkt Idx Inv
2.68
State Street Corp
2.42
iShares Russell 2000 ETF
2.36
Geode Capital Management, LLC
2.1
Vanguard Institutional Extnd Mkt Idx Tr
1.41

Market Status

Fundamentals
Market Cap
141.44 mln
PB Ratio
0.93
PE Ratio
0
Enterprise Value
33.78 mln
Total Assets
151.66 mln
Volume

Company Financials

Fund house & investment objective

Company Information
Cassava Sciences, Inc., a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a small molecule drug, which is completed Phase 2 clinical trial; and investigational diagnostic product candidate is SavaDx, a blood-based biomarker/diagnostic to detect Alzheimer's disease. The company was formerly known as Pain Therapeutics, Inc. and changed its name to Cassava Sciences, Inc. in March 2019. Cassava Sciences, Inc. was incorporated in 1998 and is based in Austin, Texas.
Organisation
Cassava Sciences Inc
Employees
29
Industry
Biotechnology
CEO
Mr. Richard Jon Barry
Trading and brokerage services provided by
Technology Services provided by Motilal Oswal Financial Services:

Take your next step

Get expert assistance for portfolio management

BUY
SELL
Click here to see your activities